Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio
  • Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2
  • Approximately 140,000 Americans live with IPF, a rare disease with no cure, and 50,000 new cases are diagnosed annually3
  • Sandoz is committed to developing and providing patient access to high-quality, more affordable generic medicines, especially in areas of high unmet need

Princeton, May 12, 2022 — Sandoz, a global leader in …